Herrick Represents Cardax Pharma In Reverse Merger With Koffee Korner Inc.

March 3, 2014 – Press Release
Herrick, Feinstein LLP

Herrick, Feinstein LLP is pleased to have represented Cardax Pharma, Inc., a development stage life sciences company, in its successful reverse merger with OTCBB-traded Koffee Korner Inc. In connection with the transaction, which closed on February 7, 2014, Koffee Korner Inc. changed its name to Cardax, Inc. and changed its trading symbol to "CDXI".

The Herrick deal team advising Cardax was led by partner Louis Tuchman along with Liliana Chang.

"We turned to Herrick's Corporate Department because of their practical, business-minded approach for middle-market companies," said David G. Watumull, President and Chief Executive Officer of Cardax. "They provided us with efficient solutions that helped us successfully reach our goals of raising capital and going public through this alternative IPO structure" said Nicholas Mitsakos, Executive Chairman of Cardax.

About Herrick, Feinstein LLP:

Founded in 1928, Herrick, Feinstein LLP is a prominent law firm headquartered in New York City providing a full range of legal services, including corporate and securities, real estate, art law, bankruptcy and business reorganization, commercial litigation, employment law, government relations, insurance, intellectual property, sports law, and tax and personal planning.

Herrick's Corporate Department has a track record of successes representing major clients across the country and around the world, including many Fortune 1000 firms.

Herrick's Public Companies Group provides comprehensive legal solutions that encompass traditional public company transactional and capital markets advice, as well as strategic guidance on a full array of commercial and legal issues faced by companies, their directors and officers, and board committees. Using a multi-disciplinary team approach, Herrick delivers pragmatic and cost effective service across a wide range of legal disciplines – including securities regulation, corporate finance and business combination transactions, ERISA, executive compensation, enterprise risk management and governmental and internal investigations.